Neos Theraps

Neos Therapeutics is a specialty pharmaceutical company that focused on the development and commercialization of extended-release (XR) products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The company leveraged its proprietary XR-ODT (Extended-Release Orally Disintegrating Tablet) and XR-Liquid technology platforms to create patient-friendly dosage forms. Its FDA-approved portfolio included Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER. In March 2021, Neos Therapeutics was acquired by Aytu BioPharma (formerly Aytu BioScience) in an all-stock transaction. The merger combined Neos's ADHD franchise with Aytu's diversified portfolio of consumer health and prescription products. The company's manufacturing facility in Grand Prairie, Texas, continues to support the production of these specialized formulations.